AR066240A1 - Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 - Google Patents
Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13Info
- Publication number
- AR066240A1 AR066240A1 ARP080101679A ARP080101679A AR066240A1 AR 066240 A1 AR066240 A1 AR 066240A1 AR P080101679 A ARP080101679 A AR P080101679A AR P080101679 A ARP080101679 A AR P080101679A AR 066240 A1 AR066240 A1 AR 066240A1
- Authority
- AR
- Argentina
- Prior art keywords
- variable domain
- seq
- antibody molecule
- domain sequence
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
Métodos y composiciones para reducir o inhibir, o prevenir o demorar el inicio de uno o varios síntomas asociados con una fase temprana y/o tardía de un trastorno o una afeccion asociada con IL-13 usando agentes de union a IL-13. También se revelanmétodos para evaluar la cinética y/o la eficacia de un agente de union a IL-13 en el tratamiento o la prevencion de un trastorno o una afeccion asociada con IL-13 en un sujeto, por ejemplo, un sujeto humano. Reivindicacion 1: Un método para evaluaruna molécula de anticuerpo anti-IL-13; que comprende: proporcionar un valor de ensayo medio para al menos un parámetro farmacocinético/farmacodinámico (PK/PD) de la molécula de anticuerpo anti-IL-13 en un sujeto; y comparar el valor de ensayo medioproporcionado con al menos un valor de referencia medio, evaluando de esta forma la molécula de anticuerpo anti-IL-13, en donde el valor de referencia medio se selecciona del grupo que consiste en: un valor de CL medio en el rango deaproximadamente 0,05 a 0,9 ml/hr/kg luego de la administracion intravenosa de la molécula de anticuerpo anti-IL-13 al sujeto; un valor de Vdss medio de menos de aproximadamente 150 ml/kg luego de la administracion intravenosa al sujeto; una vidamedia promedio (t1/2) de aproximadamente 500 a 800 horas luego de la administracion intravenosa a un humano, una concentracion máxima media normalizada por dosis en suero o plasma de aproximadamente 2 a 40 mg/ml luego de la administracionintravenosa al sujeto, o aproximadamente 0,1 a 30 mg/ml luego de la administracion subcutánea al sujeto; una exposicion media normalizada por dosis de aproximadamente 800 a 18.000 (mghr/ml)(mg/kg) luego de la administracion intravenosa al sujeto, o400 a 18000 (mghr/ml)(mg(kg) luego de la administracion subcutánea al sujeto, una biodisponibilidad de aproximadamente 60 a 90% luego de la administracion subcutánea al sujeto, y una relacion de tejido a suero de menos de aproximadamente 0,5, endonde la molécula de anticuerpo anti-IL-13 comprende un anticuerpo de longitud completa; una vida media promedio (t1/2) de aproximadamente 0,5 a 30 horas luego de la administracion subcutánea o intravenosa al sujeto, en donde la molécula deanticuerpo anti-IL-13 comprende un sitio de union a antígeno de la molécula de anticuerpo; y un índice de clearance medio de menos de 0,004 ml/hr/kg luego de la administracion al sujeto, en donde la molécula de anticuerpo anti-IL-13 forma uncomplejo con IL-13. Reivindicacion 18: El método de cualquiera de las reivindicaciones 1, 2, 11, 12, 14 o 17, en donde la molécula de anticuerpo anti-IL-13 comprende una secuencia de dominio variable de inmunoglobulina de cadena pesada y unasecuencia de dominio variable de inmunoglobulina de cadena liviana que forman un sitio de union a antígeno que se une a IL-13 con un valor KD de menos de 10-7 M, en donde la molécula de anticuerpo tiene una o varias de las siguientes propiedades:(a) la secuencia de dominio variable de inmunoglobulina de cadena pesada comprende una CDR3 de cadena pesada que difiere en menos de 3 sustituciones de aminoácido de una CDR3 de cadena pesada de mAb MJ2-7; (b) la secuencia de dominio variable deinmunoglobulina de cadena liviana comprende una CDR de cadena liviana que difiere en menos de 3 sustituciones de aminoácido de una correspondiente CDR de cadena liviana de mAb MJ2-7; (c) la secuencia de dominio variable de inmunoglobulina de cadenapesada comprende una secuencia codificada por un ácido nucleico que hibrida en condiciones de alta rigurosidad al complemento de un ácido nucleico que codifica un dominio variable de cadena pesada de V2.1, V2.3, V2.4, V2.5, V2.6, V2.7 o V2.11; (d)la secuencia de dominio variable de inmunoglobulina de cadena liviana comprende una secuencia codificada por un ácido nucleico que hibrida en condiciones de alta rigurosidad al complemento de un ácido nucleico que codifica un dominio variable decadena liviana de V2.11; (e) la secuencia de dominio variable de inmunoglobulina de cadena pesada es al menos 90% idéntica a un dominio variable de cadena pesada de V2.1, V2.3, V2.4, V2.5, V2.6, V2.7 o V2. 11; (f) la secuencia de dominio variable deinmunoglobulina de cadena liviana es al menos 90% idéntica a un dominio variable de cadena liviana de V2.11; (g) la molécula de anticuerpo compite con mAb MJ2-7 por la union a IL-13 humana; (h) la molécula de anticuerpo se pone en contacto con uno ovarios aminoácido de IL-13 seleccionados del grupo que consiste en los residuos 116, 117, 118, 122, 123, 124, 125, 126, 127 y 128 de SEQ ID N°:24 o SEQ ID N°:178; (i) la secuencia de dominio variable de cadena pesada tiene la misma estructuracanonica que mAb MJ27 en los bucles hipervariables 1, 2 y/o 3; (j) la secuencia de dominio variable de cadena liviana tiene la misma estructura canonica que mAb MJ2-7 en los bucles hipervariables 1, 2 y/o 3; y (k) la secuencia de dominio variable decadena pesada y/o la secuencia de dominio variable de cadena liviana tiene regiones de marco FR1, FR2 y FR3 de segmentos de VH codificados por los genes de línea germinal DP-54 y DPK-9, respectivamente, o una secuencia al menos 95% idéntica asegmentos de VH codificados por los genes de línea germinal DP-54 y DPK-9. Reivindicacion 19: El método de la reivindicacion 18, en donde la molécula de anticuerpo anti-IL-13 es un anticuerpo de longitud completa o un fragmento de éste. Reivindicacion 21: El método de la reivindicacion 18, en donde la molécula de anticuerpo anti-IL-13 comprende una secuencia de dominio variable de cadena pesada que tiene una secuencia: (i) G-(YF)-(NT)-l-K-D-T-Y-(MI)-H (SEQ ID N°:48), en CDR1,(ii) (WR)-I-D-P-(GA)-N-D-N-I-K-Y-(SD)-(PQ)-K-F-Q-G (SEQ ID N°:49), en CDR2, y (iii) SEENWYDFFDY (SEQ ID N°;17), en CDR3; y una secuencia de dominio variable de cadena liviana que tiene la secuencia (i) (RK)-S-S-Q-S-(LI)-(KV)-H-S-(ND)-G-N-(TN)-Y-L-(EDNQYAS) (SEQ ID N°:25), en CDR1; (ii) K-(LVI)-S-(NY)-(RW)-(FD)-S (SEQ ID N°:27), en CDR2, y (iii) Q-(GSA)-(ST)-(HEQ)-I-P (SEQ ID N°:28), en CDR3. Reivindicacion 22: El método de la reivindicacion 18, en donde la molécula de anticuerpo anti-IL-13comprende una secuencia de dominio variable de cadena pesada que tiene una secuencia: GFNlKDTYIH (SEQ ID N° 15), en CDR1, RIDPANDNIKYDPKFQG (SEQ ID N°:16), en CDR2, y (iii) SEENWYDFFDY (SEQ ID N°;17), en CDR3; una secuencia de dominio variable decadena liviana que tiene la secuencia: RSSQSIVHSNGNTYLE (SEQ ID N°:18), en CDR1; (ii) KVSNRFS (SEQ ID N°:19), en CDR2, y (iii) FQGSHIPYT (SEQ ID N°:20), en CDR3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92607807P | 2007-04-23 | 2007-04-23 | |
US92593207P | 2007-04-23 | 2007-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066240A1 true AR066240A1 (es) | 2009-08-05 |
Family
ID=39689094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101679A AR066240A1 (es) | 2007-04-23 | 2008-04-22 | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090068195A1 (es) |
EP (1) | EP2137215A2 (es) |
JP (1) | JP2010527916A (es) |
CN (1) | CN101977935A (es) |
AR (1) | AR066240A1 (es) |
BR (1) | BRPI0810561A2 (es) |
CA (1) | CA2685123A1 (es) |
CL (1) | CL2008001182A1 (es) |
MX (1) | MX2009011366A (es) |
PA (1) | PA8778101A1 (es) |
PE (1) | PE20090154A1 (es) |
RU (1) | RU2009140134A (es) |
TW (1) | TW200848429A (es) |
WO (1) | WO2008131376A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
GB0509512D0 (en) * | 2005-05-10 | 2005-06-15 | Novartis Ag | Organic compounds |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
BRPI0910482A2 (pt) * | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
EP2297209A4 (en) * | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
WO2009149185A2 (en) * | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US8822645B2 (en) * | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
GB0905972D0 (en) | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
UY32870A (es) * | 2009-09-01 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CN102573904B (zh) * | 2009-10-08 | 2016-02-10 | 阿昂梅迪克斯公司 | 含有源于室内空气的细胞外小泡的组合物及其用途 |
RU2012119756A (ru) * | 2009-10-15 | 2013-11-20 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
PE20131412A1 (es) | 2010-08-03 | 2014-01-19 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
AU2011323521A1 (en) * | 2010-11-02 | 2013-06-20 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
EP3461847B1 (en) | 2010-12-06 | 2020-09-23 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
TWI666447B (zh) | 2010-12-16 | 2019-07-21 | 建南德克公司 | 關於th2抑制作用之診斷及治療 |
JP6248029B2 (ja) * | 2011-03-31 | 2017-12-13 | ジェネンテック, インコーポレイテッド | ベータ7インテグリンアンタゴニストの投与方法 |
JP2014520847A (ja) * | 2011-07-13 | 2014-08-25 | アッヴィ・インコーポレイテッド | 抗il−13抗体を使用して喘息を治療するための方法および組成物 |
AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
NZ628458A (en) * | 2012-03-27 | 2016-11-25 | Genentech Inc | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
WO2013181696A1 (en) * | 2012-06-05 | 2013-12-12 | The Australian National University | Vaccination with interleukin-4 antagonists |
MY171664A (en) | 2012-11-01 | 2019-10-22 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof |
CA2904448A1 (en) | 2013-03-15 | 2014-09-18 | Tariq Ghayur | Dual specific binding proteins directed against il-1.beta. and/or il-17 |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
LT3331902T (lt) | 2015-08-07 | 2021-08-10 | ALX Oncology Inc. | Konstruktai, turintys sirp-alfa domeną arba jo variantą |
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
CN109705217B (zh) * | 2017-10-25 | 2020-09-11 | 北京智仁美博生物科技有限公司 | 抗il-13抗体及其用途 |
EP3843772A2 (en) * | 2018-08-31 | 2021-07-07 | ALX Oncology Inc. | Decoy polypeptides |
JP2022528324A (ja) * | 2019-03-26 | 2022-06-10 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 抗il13r抗体またはその結合フラグメントを用いた治療 |
EP3976099A1 (en) | 2019-05-31 | 2022-04-06 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
AU643427B2 (en) * | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5246701A (en) * | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
EP0506574B1 (fr) * | 1991-03-29 | 1995-11-29 | Sanofi | Protéine à activité de type cytokine, ADN recombinant codant pour cette protéine, cellules et microorganismes transformés |
LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
DK0721469T3 (da) * | 1993-09-02 | 2000-05-01 | Dartmouth College | Anti-gp39-antistoffer og anvendelse deraf |
US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US6911530B1 (en) * | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) * | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
US7078494B1 (en) * | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
US6387615B2 (en) * | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
WO1999029888A1 (en) * | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
NZ512942A (en) * | 1998-12-14 | 2004-01-30 | Univ Johns Hopkins | Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB0004016D0 (en) * | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
WO2001077332A2 (en) * | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
CA2433353C (en) * | 2000-12-28 | 2017-03-21 | Altus Biologics, Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
AUPR544401A0 (en) * | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
CA2450147A1 (en) * | 2001-06-07 | 2002-12-19 | Wyeth | Solution structure of il-13 and uses thereof |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20040248260A1 (en) * | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
US20040234499A1 (en) * | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
AU2002361122A1 (en) * | 2001-11-27 | 2003-06-10 | Mochida Pharmaceutical Co., Ltd. | ANTI-IL13 RECEPTOR Alpha1 NEUTRALIZING ANTIBODY |
EP1455833A1 (en) * | 2001-12-04 | 2004-09-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
CA2480059C (en) * | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
AU2003243189B2 (en) * | 2002-05-01 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
NZ537726A (en) * | 2002-06-14 | 2008-06-30 | Brigham & Womens Hospital | Methods of treating and preventing colitis involving IL-13 and NK-T cells |
JP2004121218A (ja) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
DK3718564T3 (da) * | 2003-12-23 | 2023-11-06 | Genentech Inc | Nye anti-IL-13-antistoffer og anvendelser |
JP2007525210A (ja) * | 2003-12-24 | 2007-09-06 | ワイス | 喘息の処置方法 |
EP1713441A2 (en) * | 2004-02-12 | 2006-10-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
EP1720573A4 (en) * | 2004-02-27 | 2008-04-02 | Centocor Inc | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13 |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
CA2672215A1 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
-
2008
- 2008-04-22 TW TW097114612A patent/TW200848429A/zh unknown
- 2008-04-22 EP EP08746533A patent/EP2137215A2/en not_active Withdrawn
- 2008-04-22 CN CN2008800213299A patent/CN101977935A/zh active Pending
- 2008-04-22 BR BRPI0810561A patent/BRPI0810561A2/pt not_active IP Right Cessation
- 2008-04-22 WO PCT/US2008/061130 patent/WO2008131376A2/en active Application Filing
- 2008-04-22 RU RU2009140134/10A patent/RU2009140134A/ru not_active Application Discontinuation
- 2008-04-22 US US12/107,456 patent/US20090068195A1/en not_active Abandoned
- 2008-04-22 CA CA002685123A patent/CA2685123A1/en not_active Abandoned
- 2008-04-22 AR ARP080101679A patent/AR066240A1/es unknown
- 2008-04-22 JP JP2010506427A patent/JP2010527916A/ja not_active Withdrawn
- 2008-04-22 MX MX2009011366A patent/MX2009011366A/es not_active Application Discontinuation
- 2008-04-23 PA PA20088778101A patent/PA8778101A1/es unknown
- 2008-04-23 CL CL2008001182A patent/CL2008001182A1/es unknown
- 2008-04-23 PE PE2008000699A patent/PE20090154A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2008131376A3 (en) | 2009-02-05 |
TW200848429A (en) | 2008-12-16 |
CL2008001182A1 (es) | 2009-01-16 |
JP2010527916A (ja) | 2010-08-19 |
BRPI0810561A2 (pt) | 2019-09-24 |
CA2685123A1 (en) | 2008-10-30 |
PE20090154A1 (es) | 2009-03-31 |
CN101977935A (zh) | 2011-02-16 |
EP2137215A2 (en) | 2009-12-30 |
PA8778101A1 (es) | 2008-11-19 |
RU2009140134A (ru) | 2011-05-27 |
WO2008131376A2 (en) | 2008-10-30 |
US20090068195A1 (en) | 2009-03-12 |
MX2009011366A (es) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066240A1 (es) | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 | |
EP3334431B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
EP2850101B1 (en) | Anti-fcrn antibodies | |
ES2593754T3 (es) | Anticuerpos anti-IL-23 | |
BR112020002012A2 (pt) | anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
BR122020025583B1 (pt) | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão | |
RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
JP2020503001A5 (es) | ||
JP2011518546A5 (es) | ||
JP2009529920A5 (es) | ||
RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
JP2019528048A (ja) | Egfr結合分子 | |
US20210277131A1 (en) | TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF | |
JP2015503909A5 (es) | ||
AU2011278227B2 (en) | Superior efficacy of CD37 antibodies in CLL blood samples | |
HUE026058T2 (en) | c-Met monoclonal antibodies | |
JPWO2020068752A5 (es) | ||
EP3504244A1 (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
JP2013534515A5 (ja) | 受容体型チロシンキナーゼc−Metに対する抗体 | |
BR112020016986A2 (pt) | formulações de anticorpo contra b7-h4 | |
JP2015518857A5 (es) | ||
CN111183157A (zh) | Cd138抗体分子及其用途 | |
EP3180356A1 (en) | Human anti-fgfr4 antibody | |
JP2016501877A5 (es) | ||
IL294661A (en) | Antibody molecules for c5ar1 and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |